Evolent Health, Inc. (EVH) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026. Evolent Health, Inc. operates as a holding company for Evolent Health LLC, a market leader in connecting care for patients with complex conditions (e.g., cancer, cardiovascular disease) on behalf of health plans and payers. The company operates in a single reportable segment.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue | $652.5 million | $444.3 million | $1,148.8 million | $928.0 million |
| Cost of Revenue | $571.7 million | $343.9 million | $984.2 million | $725.1 million |
| Gross Margin | 12.4% | 22.6% | 14.3% | 21.9% |
| Operating Loss | $(9.6) million | $(1.2) million | $(20.2) million | $(2.8) million |
| Net Loss (Common Shareholders) | $(28.4) million | $(51.1) million | $(55.0) million | $(123.3) million |
| Diluted EPS | $(0.25) | $(0.44) | $(0.49) | $(1.07) |
| Cash & Equivalents | $115.7 million | $151.9 million | $115.7 million | $151.9 million |
| Long-Term Debt (Net) | $966.5 million | $970.5 million | $966.5 million | $970.5 million |
Liquidity: As of June 30, 2026, the company held $115.7 million in unrestricted cash and $25.8 million in restricted cash. Management believes this is sufficient for the next 12 months.
Medical Expense Ratio (MER): For the six months ended June 30, 2026, the MER for the Performance Suite was 94.5%, compared to 73.6% in the prior year period, driven by new contract go-lives.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 46.9% QoQ and 23.8% YTD, primarily driven by $216.8 million (Q2) and $339.8 million (YTD) in growth from new Performance Suite contracts and expanded oncology services.
- Margin Compression: Gross margins declined significantly due to higher medical claims costs associated with new Performance Suite contracts. Cost of revenue increased 66.2% QoQ, outpacing revenue growth.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses decreased 8.5% QoQ and 7.8% YTD due to reduced headcount, lower severance, and lower professional fees following the disposition of Evolent Care Partners (ECP) in December 2025.
- Debt Structure: In August 2025, the company issued $166.8 million in 2031 Convertible Notes and exchanged its Series A Preferred Stock for a Second Lien Term Loan Facility ($175.0 million principal).
- Disposals: The company sold Evolent Care Partners in Q4 2025, resulting in a $14.9 million gain in the prior year and eliminating related revenue streams in the current period.
Outlook, Risks, and Contingencies
- Industry Dynamics: The company notes industry-wide increases in medical claims costs and higher disease prevalence. Changes in Medicaid and ACA Health Exchanges (including the "One Big Beautiful Bill Act" passed in 2025) have led to membership declines and higher member acuity.
- Guidance: Management anticipates exchange membership attrition to continue through the end of 2026, though at a decreasing pace. No specific numerical guidance for full-year 2026 revenue or earnings was provided in this text.
- Legal Proceedings:
- DOJ Investigation: Received a Civil Investigative Demand (CID) in August 2025 regarding a False Claims Act investigation concerning a former customer (not a customer since 2021) and unsupported diagnosis codes. The company cannot estimate potential losses.
- Derivative Action: A shareholder derivative action regarding oversight of a former relationship with University Healthcare, Inc. was dismissed without prejudice in 2023, but a subsequent demand for investigation was refused by the Board in February 2024.
- Key Risks: Significant concentration of revenue from top partners (Molina, Highmark, Cook County); reliance on performance-based contracts; potential for goodwill impairment; and regulatory changes in healthcare.
Investor Verification Checklist
- Medical Expense Ratio (MER) Trajectory: Verify if the elevated MER (94.5% YTD) stabilizes as new Performance Suite contracts mature and clinical interventions take effect.
- Membership Trends: Monitor the impact of the "One Big Beautiful Bill Act" and exchange attrition on future revenue growth and member counts.
- Debt Service Capacity: Assess the ability to service ~$1.1 billion in debt obligations (including Term Loans and Convertible Notes) given the current operating loss.
- DOJ Investigation Outcome: Track the status of the False Claims Act investigation regarding the former customer to assess potential liability.
- Partner Concentration: Review the stability of contracts with top partners (Molina, Highmark, Cook County) which represent a significant portion of revenue.